Table A2.
Risk Factors for Overall Mortality and Nonrelapse Mortality in Multivariate Analysis
| Variable | Overall Mortality |
Nonrelapse Mortality |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| All patients* | ||||||
| Age at HCT, years | ||||||
| < 60 | 1.0 | .92 | 1.0 | .92 | ||
| ≥ 60 | 0.98 | 0.7 to 1.4 | 0.97 | 0.5 to 1.7 | ||
| AML etiology | ||||||
| De novo | 1.0 | .50 | 1.0 | .34 | ||
| Secondary | 0.87 | 0.6 to 1.3 | 0.74 | 0.4 to 1.4 | ||
| AML stage | ||||||
| CR1 | 1.0 | < .001 | 1.0 | .10 | ||
| CR2 | 1.90 | 1.2 to 3.1 | 1.08 | 0.5 to 2.6 | ||
| Advanced/refractory | 4.92 | 2.8 to 8.7 | 2.49 | 0.9 to 6.5 | ||
| Cytogenetic risk | ||||||
| Favorable/intermediate | 1.0 | .002 | 1.0 | .18 | ||
| Unfavorable | 2.12 | 1.4 to 3.2 | 1.57 | 0.8 to 3.1 | ||
| Unknown prognostic significance | 1.60 | 1.0 to 2.6 | 1.90 | 0.9 to 3.9 | ||
| Months from diagnosis to HCT | ||||||
| < 6 | 1.0 | .005 | 1.0 | .92 | ||
| 6-18 | 0.85 | 0.5 to 1.4 | 0.98 | 0.5 to 2.1 | ||
| ≥ 18 | 0.38 | 0.2 to 0.7 | 1.15 | 0.4 to 3.3 | ||
| HCT-CI score | ||||||
| 0-1 | 1.0 | .36 | 1.0 | .08 | ||
| 2-3 | 1.36 | 0.9 to 2.1 | 1.70 | 0.9 to 3.3 | ||
| ≥ 4 | 1.26 | 0.8 to 2.0 | 2.20 | 1.1 to 4.5 | ||
| Donor | ||||||
| HLA-identical sibling | 1.0 | .04 | 1.0 | .003 | ||
| HLA-matched unrelated donor | 1.35 | 0.9 to 2.0 | 1.86 | 1.0 to 3.6 | ||
| HLA-mismatched unrelated donor | 2.07 | 1.2 to 3.6 | 3.91 | 1.8 to 8.6 | ||
| Patients in CR1 (n = 130) | ||||||
| Age at HCT, years | ||||||
| < 60 | 1.0 | .93 | 1.0 | .81 | ||
| ≥ 60 | 1.02 | 0.6 to 1.7 | 1.10 | 0.5 to 2.4 | ||
| AML etiology | ||||||
| De novo | 1.0 | .28 | 1.0 | .24 | ||
| Secondary | 0.73 | 0.4 to 1.3 | 0.57 | 0.2 to 1.5 | ||
| Cytogenetic risk | ||||||
| Favorable/intermediate | 1.0 | .05 | 1.0 | .81 | ||
| Unfavorable | 2.02 | 1.1 to 3.7 | 1.37 | 0.5 to 3.6 | ||
| Unknown prognostic significance | 0.98 | 0.5 to 1.9 | 1.21 | 0.5 to 3.1 | ||
| Months from diagnosis to HCT | ||||||
| < 6 | 1.0 | .97 | 1.0 | .92 | ||
| ≥ 6 | 0.99 | 0.6 to 1.7 | 1.04 | 0.5 to 2.4 | ||
| HCT-CI score | ||||||
| 0-1 | 1.0 | .32 | 1.0 | .25 | ||
| 2-3 | 1.54 | 0.9 to 2.7 | 2.03 | 0.8 to 4.9 | ||
| ≥ 4 | 1.36 | 0.7 to 2.7 | 1.92 | 0.7 to 5.6 | ||
| Donor | ||||||
| HLA-identical sibling | 1.0 | .48 | 1.0 | .05 | ||
| HLA-matched unrelated donor | 1.20 | 0.7 to 2.1 | 1.79 | 0.7 to 4.4 | ||
| HLA-mismatched unrelated donor | 1.75 | 0.7 to 4.2 | 5.04 | 1.4 to 18 | ||
NOTE. The effects of the No. of high-dose chemotherapy cycles before HCT, pre-HCT peripheral-blood cell count recovery, and minimal residual disease on risks of mortality and nonrelapse mortality were also analyzed in this multivariate model and were not found to be statistically significant.
Abbreviations: HR, hazard ratio; HCT, hematopoietic cell transplantation; AML, acute myeloid leukemia; CR1, first complete remission; CR2, second complete remission; CI, comorbidity index.
*
Data on all variables were available for 226 patients undergoing HCT with nonmyeloablative conditioning.